Claims
- 1. A method for detecting a binding event between at least two components and C-reactive protein, the method comprising the steps of
introducing a solution containing C-reactive protein; adding to the solution at least one donor component comprising at least one compound that binds C-reactive protein and emits a signal after a light source excites the compound; adding to the solution at least one acceptor component comprising at least one compound that binds C-reactive protein and that receives the signal and emits it in the form of electromagnetic radiation. exciting the donor component with a light source; detecting the electromagnetic radiation emitted by the acceptor component.
- 2. The method of claim 1, wherein the step of adding the at least one donor component further comprises adding a group of donor components.
- 3. The method of claim 1, wherein the at least one donor component further comprises a group of compounds that emit a signal after a light source excites them.
- 4. The method of claim 1, wherein the at least one donor component binds directly via one or more components to C-reactive protein.
- 5. The method of claim 1, wherein the at least one donor component binds indirectly via one or more components to C-reactive protein.
- 6. The method claim 1, wherein the step of adding the at least one acceptor component further comprises adding a group of acceptor components.
- 7. The method of claim 1, wherein the at least one acceptor component further comprises a group of compounds.
- 8. The method of claim 1, wherein the at least one acceptor component binds directly via one or more components to C-reactive protein.
- 9. The method of claim 1, wherein the at least one acceptor component binds indirectly via one or more components to C-reactive protein.
- 10. The method of claim 1, wherein the electromagnetic radiation is fluorescence radiation.
- 11. The method of claim 1, wherein the light source is selected from the group consisting of a laser and a lamp.
- 12. The method of claim 1, further comprising detecting with a photomultiplier the electromagnetic radiation emitted by the at least one acceptor component.
- 13. The method of claim 1, wherein the at least one donor component and at least one acceptor component bind, in spatial succession, to the C-reactive protein or to each other.
- 14. The method of claim 1, wherein the at least one donor component and at least one acceptor component comprise polypeptides.
- 15. The method of claim 14, wherein at least one of the components is an antibody.
- 16. The method of claim 15, wherein the antibody is selected from the group consisting of a monoclonal or polyclonal antibody.
- 17. The method of claim 1, wherein at least one of the components is a natural binding partner of the C-reactive protein.
- 18. The method of claim 17, wherein the natural binding partner is C1q.
- 19. The method of claim 18, wherein the at least one donor component or at least one acceptor component comprises C1q and an anti-C1q antibody.
- 20. The method of claim 1, wherein the signal is transferred from the at least one donor component to the at least one acceptor component by emissionless energy transfer.
- 21. The method of claim 20, wherein the emissionless energy transfer is a fluorescence resonance energy transfer.
- 22. The method of claim 1, wherein the signal is transferred from the at least one donor component to the at least one acceptor component via singlet oxygen.
- 23. The method of claim 1, wherein the at least one donor component comprises a compound which is able to convert triplet oxygen to singlet oxygen after excitation by a laser and wherein the at least one acceptor group comprises at least one first compound excitable by singlet oxygen and at least one second compound capable of absorbing in an emissionless manner and emitting in the form of fluorescence radiation the energy absorbed by the first compound.
- 24. The method of claim 23, wherein the donor group and the acceptor group are localized on particles.
- 25. The method of claimed in claim 24, wherein the particles have an average diameter of approximately 200 nm.
- 26. The method of claim 1, further comprising the step of determining the concentration of C-reactive protein in the solution.
- 27. The method of claim 26, wherein the solution is selected from the group consisting of blood serum, blood plasma, blood serum diluted by a physiological buffer, blood serum diluted by water, blood plasma diluted by a physiological buffer, and blood plasma diluted by water.
- 28. The method of claim 1, further comprising the steps of
adding at least one test substance; and observing whether the test substance influences the binding event between C-reactive protein and the at least two components.
- 29. A method for detecting a binding event between at least two components and C1q, the method comprising the steps of
introducing a solution containing C1q; adding to the solution at least one donor component comprising at least one compound that binds C1q and emits a signal after a light source excites the compound; adding to the solution at least one acceptor component comprising at least one compound that binds C1q and that receives the signal and emits it in the form of electromagnetic radiation. exciting the donor component with a light source; detecting the electromagnetic radiation emitted by the acceptor component.
- 30. The method of claim 29, wherein the step of adding the at least one donor component further comprises adding a group of donor components.
- 31. The method of claim 29, wherein the at least one donor component further comprises a group of compounds that emit a signal after a light source excites them.
- 32. The method of claim 29, wherein the at least one donor component binds directly via one or more components to C1q.
- 33. The method of claim 29, wherein the at least one donor component binds indirectly via one or more components to C1q.
- 34. The method claim 29, wherein the step of adding the at least one acceptor component further comprises adding a group of acceptor components.
- 35. The method of claim 29, wherein the at least one acceptor component further comprises a group of compounds.
- 36. The method of claim 29, wherein the at least one acceptor component binds directly via one or more components to C1q.
- 37. The method of claim 29, wherein the at least one acceptor component binds indirectly via one or more components to C1q.
- 38. The method of claim 29, wherein the electromagnetic radiation is fluorescence radiation.
- 39. The method of claim 29, wherein the light source is selected from the group consisting of a laser and a lamp.
- 40. The method of claim 29, further comprising detecting with a photomultiplier the electromagnetic radiation emitted by the at least one acceptor component.
- 41. The method of claim 29, wherein the at least one donor component and at least one acceptor component bind, in spatial succession, to the C1q or to each other.
- 42. The method of claim 29, wherein the at least one donor component and at least one acceptor component comprise polypeptides.
- 43. The method of claim 42, wherein at least one of the components is an antibody.
- 44. The method of claim 43, wherein the antibody is selected from the group consisting of a monoclonal or polyclonal antibody.
- 45. The method of claim 29, wherein at least one of the components is a natural binding partner of the C1q.
- 46. The method of claim 45, wherein the natural binding partner is C-reactive protein.
- 47. The method of claim 46, wherein the at least one donor component or at least one acceptor component comprises C-reactive protein and an anti-C-reactive protein antibody.
- 48. The method of claim 29, wherein the signal is transferred from the at least one donor component to the at least one acceptor component by emissionless energy transfer.
- 49. The method of claim 48, wherein the emissionless energy transfer is a fluorescence resonance energy transfer.
- 50. The method of claim 29, wherein the signal is transferred from the at least one donor component to the at least one acceptor component via singlet oxygen.
- 51. The method of claim 29, wherein the at least one donor component comprises a compound which is able to convert triplet oxygen to singlet oxygen after excitation by a laser and wherein the at least one acceptor group comprises at least one first compound excitable by singlet oxygen and at least one second compound capable of absorbing in an emissionless manner and emitting in the form of fluorescence radiation the energy absorbed by the first compound.
- 52. The method of claim 51, wherein the donor group or the acceptor group are localized on particles.
- 53. The method of claim 52, wherein the particles have an average diameter of approximately 200 nm.
- 54. The method of claim 29, further comprising the step of determining the concentration of C-reactive protein in the solution.
- 55. The method of claim 54, wherein the solution is selected from the group consisting of blood serum, blood plasma, blood serum diluted by a physiological buffer, blood serum diluted by water, blood plasma diluted by a physiological buffer, and blood plasma diluted by water.
- 56. The method of claim 29, further comprising the steps of
adding at least one test substance; and observing whether the test substance influences the binding event between C-reactive protein and the at least two components.
- 57. An HTS-capable, diagnostic assay system for determining a binding event between C-reactive protein and a component binding to C-reactive protein, comprising:
at least one donor component comprising at least one compound that binds C-reactive protein and emits a signal after a light source excites the compound; and at least one acceptor component comprising at least one compound that binds C-reactive protein and that receives the signal and emits it in the form of electromagnetic radiation.
- 58. The assay system of claim 57, further comprising a group of donor components.
- 59. The assay system of claim 57, wherein the at least one donor component further comprises a group of compounds that emit a signal after a light source excites them.
- 60. The assay system of claim 57, wherein the at least one donor component binds directly via one or more components to C-reactive protein.
- 61. The assay system of claim 57, wherein the at least one donor component binds indirectly via one or more components to C-reactive protein.
- 62. The assay system of claim 57, wherein the at least one acceptor component further comprises a group of acceptor components.
- 63. The assay system of claim 57, wherein the at least one acceptor component further comprises a group of compounds.
- 64. The assay system of claim 57, wherein the at least one acceptor component binds directly via one or more components to C-reactive protein.
- 65. The assay system of claim 57, wherein the at least one acceptor component binds indirectly via one or more components to C-reactive protein.
- 66. The assay system of claim 57, further comprising:
a solution selected from the group consisting of blood serum, blood plasma, blood serum diluted by a physiological buffer, blood serum diluted by water, blood plasma diluted by a physiological buffer, and blood plasma diluted by water; a light source for exciting the at least one donor component; and a detection system for detecting the electromagnetic radiation emitted by the at least one acceptor component.
- 67. An HTS-capable, diagnostic assay system for determining a binding event between C1q and a component binding to C1q, comprising:
at least one donor component comprising at least one compound that binds C1q and emits a signal after a light source excites the compound; and at least one acceptor component comprising at least one compound that binds C1q and that receives the signal and emits it in the form of electromagnetic radiation.
- 68. The assay system of claim 67, further comprising a group of donor components.
- 69. The assay system of claim 67, wherein the at least one donor component further comprises a group of compounds that emit a signal after a light source excites them.
- 70. The assay system of claim 67, wherein the at least one donor component binds directly via one or more components to C1q.
- 71. The assay system of claim 67, wherein the at least one donor component binds indirectly via one or more components to C1q.
- 72. The assay system of claim 67, wherein the at least one acceptor component further comprises a group of acceptor components.
- 73. The assay system of claim 67, wherein the at least one acceptor component further comprises a group of compounds.
- 74. The assay system of claim 67, wherein the at least one acceptor component binds directly via one or more components to C1q.
- 75. The assay system of claim 67, wherein the at least one acceptor component binds indirectly via one or more components to C1q.
- 76. The assay system of claim 67, further comprising:
a solution selected from the group consisting of blood serum, blood plasma, blood serum diluted by a physiological buffer, blood serum diluted by water, blood plasma diluted by a physiological buffer, and blood plasma diluted by water; a light source for exciting the at least one donor component; and a detection system for detecting the electromagnetic radiation emitted by the at least one acceptor component.
Priority Claims (1)
Number |
Date |
Country |
Kind |
10226011.7 |
Jun 2002 |
DE |
|
Parent Case Info
[0001] This application claims the benefit of priority under 35 U.S.C. §119 of German Application No. 10226011.7 filed on Jun. 12, 2002, and of U.S. Provisional Application No. 60/426,945 filed on Nov. 15, 2002, the contents of both of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60426945 |
Nov 2002 |
US |